Xarelto Lawsuit News: Bernstein Liebhard LLP Notes Endorsement of New Xarelto Indication by English Regulators

Share Article

The Firm is representing individuals in Xarelto lawsuits that allege use of the blood-thinning medication caused serious complications, including uncontrollable internal bleeding.

Free Case Review
The endorsement of this new indication comes as dozens of plaintiffs in the U.S. are pursuing Xarelto lawsuits for serious complications allegedly caused by the drug, including uncontrollable internal bleeding.

As Xarelto lawsuits (http://www.xareltolawsuit2015.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that regulators in England have endorsed a new indication for the blood-thinning medication. According to a statement issued on October 22nd, the National Institute for Health and Care Excellence (NICE) has recommended Xarelto as an option for preventing blood clots in people who have had a heart attack as a result of a blockage or narrowing in one of the blood vessels in the heart. However, the statement noted that because Xarelto is associated with a higher risk of bleeding, NICE recommends clinicians undertake a careful assessment of a person’s bleeding risk prior to treatment.*

“The endorsement of this new indication comes as dozens of plaintiffs in the U.S. are pursuing Xarelto lawsuits for serious complications allegedly caused by the drug, including uncontrollable internal bleeding,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free, no-obligation Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.

Xarelto Litigation
In the U.S., Xarelto is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.* *

Court documents indicate at least 30 Xarelto lawsuits are now pending in U.S. courts, all of which were filed on behalf of individuals who allegedly suffered uncontrollable bleeding and other serious complications due to its use. In October, plaintiffs in several of these lawsuits asked the U.S. Judicial Panel on Multidistrict Litigation to consolidate all federally-filed claims before a single judge in the U.S. District Court, Southern District of Illinois for coordinated pretrial proceedings. The Panel has scheduled Oral Arguments on the matter for December 4, 2014. (In Re: Xarelto Products Liability Litigation, No. 2592)

According to court records, Xarleto lawsuits pending in the U.S. similarly allege that the drug’s manufacturers wrongly marketed it as a superior alternative to warfarin, a blood thinner that has been in use for decades. The complaints point out that while there is currently no approved antidote to reverse Xarelto bleeding, hemorrhaging associated with warfarin can be stopped via the administration of Vitamin K. Plaintiff’s also assert that the manufacturers should have recommended blood monitoring for Xarelto patients, so that physicians could adjust dosage to avoid high concentrations that have the potential to lead to life-threatening internal hemorrhaging.

Individuals who were allegedly harmed by Xarelto may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Xarelto lawsuit, please visit Bernstein Liebhard LLPs website, or call 800-511-5092 to schedule a free, no obligation case review.

*nice.org.uk/news/press-and-media/nice-draft-guidance-recommends-rivaroxaban-xarelto-to-prevent-blood-clots-in-people-who-have-had-a-heart-attack, NICE, October 22, 2014
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website